Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLC.

Cell death & disease·2026
Same author

Correction: "Not That I've Become Exceptional, But I'm Able to Make Myself Understood Better": Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers.

Neurology and therapy·2026
Same author

Feature representation for explainable CRISPR off-target prediction and base editing efficiency.

Frontiers in bioinformatics·2026
Same author

"Not That I've Become Exceptional, But I'm Able to Make Myself Understood Better": Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers.

Neurology and therapy·2026
Same author

Clinical phenotype associated with A118V mutation of PRPN gene.

Journal of neurology·2025
Same author

Donanemab eligibility in early Alzheimer's disease: A real-world study.

Journal of Alzheimer's disease : JAD·2025

Related Experiment Video

Updated: Jun 27, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Longitudinal Transcriptomic Analysis Reveals Systemic Effects of Risdiplam in Adults with Spinal Muscular Atrophy.

Maria Liguori1, Arianna Consiglio1, Eustachio D'Errico2

  • 1National Research Council, Department of Biomedicine, Institute of Biomedical Technologies, Bari Unit, 70125 Bari, Italy.

Brain Sciences
|June 26, 2026
PubMed
Summary

Risdiplam treatment increased SMN2 levels in adult Spinal Muscular Atrophy (SMA) patients, impacting mitochondrial and autophagy pathways. Molecular differences were noted between SMA types II and III.

Keywords:
RNA sequencingRisdiplamSMN2 geneTranscriptomicsspinal muscular atrophy

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Dissection of Drosophila melanogaster Flight Muscles for Omics Approaches
08:33

Dissection of Drosophila melanogaster Flight Muscles for Omics Approaches

Published on: October 17, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Dissection of Drosophila melanogaster Flight Muscles for Omics Approaches
08:33

Dissection of Drosophila melanogaster Flight Muscles for Omics Approaches

Published on: October 17, 2019

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Spinal Muscular Atrophy (SMA) is a neurodegenerative disorder resulting from reduced survival motor neuron (SMN) protein due to SMN1 gene mutations.
  • Innovative therapies like Risdiplam have altered SMA's natural history by increasing SMN protein levels.
  • Risdiplam is an oral medication that enhances SMN protein by modifying the splicing of the SMN2 gene.

Purpose of the Study:

  • To assess transcriptomic changes in adult SMA patients treated with Risdiplam.
  • To evaluate the impact of Risdiplam on SMN2 transcript levels and related cellular pathways.
  • To identify molecular distinctions between SMA type II and type III phenotypes.

Main Methods:

  • Longitudinal RNA sequencing was performed on peripheral blood samples.
  • 16 adult SMA patients (types II and III) were included in the study.
  • Samples were collected before and after 12 months of Risdiplam treatment.

Main Results:

  • Risdiplam treatment led to increased SMN2 transcript levels in SMA patients.
  • Upregulation of mitochondrial genes (e.g., MT-ATP8, MTND1P11) and downregulation of autophagy pathways were observed.
  • Baseline gene expression differences between SMA types II and III included neurodegenerative and immune-related genes (e.g., MS4A3, C4BPA, NEILS3, B2M).

Conclusions:

  • The findings support the systemic effects of Risdiplam in adult SMA patients.
  • Molecular distinctions between SMA type II and type III phenotypes were identified.
  • These molecular insights may inform future clinical and therapeutic strategies for SMA.